Trevogrumab, a myostatin/GDF8-targeted antibody candidate, demonstrated ability to prevent lean-mass reduction in patients taking GLP-1 therapy for obesity.
Trevogrumab, a myostatin/GDF8-targeted antibody candidate, demonstrated ability to prevent lean-mass reduction in patients taking GLP-1 therapy for obesity.